Wong Hoi Y, Coates Alison M, Carter Sharayah, Hill Alison M
Alliance for Research in Exercise, Nutrition and Activity (ARENA), Allied Health and Human Performance, University of South Australia, Adelaide, SA 5001, Australia.
School of Health and Biomedical Sciences, RMIT University, Bundoora, VIC 3083, Australia.
Nutr Rev. 2025 Oct 1;83(10):1843-1860. doi: 10.1093/nutrit/nuaf033.
Nut consumption is attributed to improvements in risk factors for cardiovascular disease (CVD), including high blood pressure (BP) and dyslipidemia. However, it is unclear whether these effects are altered with concurrent treatment with BP and lipid-lowering medication.
We sought to investigate the effects of the consumption of whole tree nuts and peanuts (collectively termed nuts) on BP and lipids, and whether BP and lipid-lowering medication use alters these effects.
The MEDLINE, EMBASE, Scopus, and Web of Science databases were systematically searched through June 21, 2023, for randomized controlled trials (RCTs) assessing the effects of nut consumption on BP and/or lipids.
Random effects meta-analyses (mean difference, 95% confidence interval [CI]) were conducted, with subgroup analyses based on reported participant use of BP or lipid-lowering medication, including medicated, unmedicated, unreported (ie, use not specified), and mixed (ie, included combined data from medicated and unmedicated participants). A total of 115 studies were included in the review, of which 109 were meta-analysed.
Nut consumption significantly reduced triglycerides (TG), total cholesterol, low-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B, with no effect on high-density lipoprotein cholesterol or blood pressure. Few studies were conducted in medicated participants only (n = 1 for lipid outcomes only), and for the studies including both medicated and unmedicated participants (ie, mixed), outcomes by medication use were not reported. Significant differences in TG and apolipoprotein B were observed between medication use groups, with nut consumption resulting in the largest reductions in unmedicated participants. Strong heterogeneity was observed with no evidence of publication bias.
Lipid-lowering, but not BP-lowering benefits of nut consumption were observed; however, few studies reported the effect based on participants' medication status. Future studies are required to determine if there are additional benefits of including nuts in the diet of medicated patients with cardiovascular disease.
PROSPERO registration code CRD42022296849.
食用坚果有助于改善心血管疾病(CVD)的危险因素,包括高血压(BP)和血脂异常。然而,尚不清楚在同时使用降压和降脂药物治疗时,这些效果是否会改变。
我们旨在研究食用整粒坚果和花生(统称为坚果)对血压和血脂的影响,以及使用降压和降脂药物是否会改变这些影响。
系统检索了MEDLINE、EMBASE、Scopus和Web of Science数据库,截至2023年6月21日,查找评估食用坚果对血压和/或血脂影响的随机对照试验(RCT)。
进行随机效应荟萃分析(平均差,95%置信区间[CI]),并根据报告的参与者使用降压或降脂药物的情况进行亚组分析,包括用药、未用药、未报告(即使用情况未明确说明)和混合(即包括用药和未用药参与者的合并数据)。该综述共纳入115项研究,其中109项进行了荟萃分析。
食用坚果显著降低了甘油三酯(TG)、总胆固醇、低密度脂蛋白胆固醇、极低密度脂蛋白胆固醇、非高密度脂蛋白胆固醇和载脂蛋白B,对高密度脂蛋白胆固醇或血压无影响。仅在用药参与者中进行的研究很少(仅血脂结果方面n = 1),对于包括用药和未用药参与者(即混合)的研究,未报告按用药情况的结果。在用药组之间观察到TG和载脂蛋白B存在显著差异,食用坚果使未用药参与者的降低幅度最大。观察到强烈的异质性,无发表偏倚的证据。
观察到食用坚果有降脂但无降压益处;然而,很少有研究根据参与者的用药状态报告效果。未来需要开展研究,以确定在患有心血管疾病的用药患者饮食中加入坚果是否有额外益处。
PROSPERO注册号CRD42022296849。